Læknablaðið : fylgirit - 01.06.1996, Side 79

LÆKNABLAÐIÐ 1996; 82/FYLGIRIT 31
71
was 0.54 (95% CI 0.44-0.64), NNT=5.0. Among
eight investigator-blinded trials, the RR was 0.78
(CI 0.72-0.85), NNT=14. SS was efficacious for
both peptic ulcer (RR=0.58, CI 0.48-0.70,
NNT=4.2) and for non-ulcer lesions (RR=0.62,
CI0.39-1.002). SS reduced the need for surgery
among all trials (RR=0.74, CI 0.63-0.84,
NNT=8.3), except investigator-blinded trials (RR
0.95, CI=0.90-1.007). There was no difference in
mean transfusion requirement (weighted mean dif-
ference l.lunits (CI=-0.6-2.8).
Conclusions: This meta-analysis demonstrates
that SS reduces the risk of persistent or recurrent
acute, nonvariceal UGIH, suggesting that it may
have a role in the initial management of this com-
mon clinical problem.